Corton Capital Inc. Alkermes Plc. Transaction History

Corton Capital Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$28.34 - $33.63 $258,290 - $306,503	9,114 New	9,114 $285,000
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $9,702 - $14,054	441 Added 3.86%	11,858 $265,000
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $50,582 - $58,514	1,916 Added 20.17%	11,417 $340,000
Q1 2022 May 16, 2022	SELL	$23.07 - $27.99 $121,371 - $147,255	-5,261 Reduced 35.64%	9,501 $250,000
Q4 2021 Feb 14, 2022	BUY	$21.47 - $32.08 $316,940 - $473,564	14,762 New	14,762 $343,000

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.55B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Corton Capital Inc. with notifications on news.